标题
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
作者
关键词
-
出版物
ACTA PSYCHIATRICA SCANDINAVICA
Volume 132, Issue 2, Pages 97-108
出版商
Wiley
发表日期
2015-05-28
DOI
10.1111/acps.12445
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The STRIDE Weight Loss and Lifestyle Intervention for Individuals Taking Antipsychotic Medications: A Randomized Trial
- (2015) Carla A. Green et al. AMERICAN JOURNAL OF PSYCHIATRY
- Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
- (2015) MARC DE HERT et al. World Psychiatry
- Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
- (2015) MARC DE HERT et al. World Psychiatry
- Emerging drugs for schizophrenia: an update
- (2014) Luisa-Sophie Köster et al. EXPERT OPINION ON EMERGING DRUGS
- Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats
- (2014) Qingsheng Zhang et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission
- (2014) Peter Manu et al. JOURNAL OF CLINICAL PSYCHIATRY
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013
- (2014) Marie Ng et al. LANCET
- Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
- (2014) Maarten Bak et al. PLoS One
- Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment
- (2014) Jiamei Lian et al. PLoS One
- Serum leptin and its relationship with psychopathology in schizophrenia
- (2014) Milawaty Nurjono et al. PSYCHONEUROENDOCRINOLOGY
- Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats
- (2014) Meng He et al. PSYCHONEUROENDOCRINOLOGY
- Antipsychotic Treatment and Mortality in Schizophrenia
- (2014) M. Torniainen et al. SCHIZOPHRENIA BULLETIN
- Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis
- (2014) Rocio Pérez-Iglesias et al. SCHIZOPHRENIA RESEARCH
- Markers of inflammation in schizophrenia: association vs. causation
- (2014) Peter Manu et al. World Psychiatry
- Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes
- (2013) Olubukola Ajala et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Metformin for Antipsychotic-Related Weight Gain and Metabolic Abnormalities: When, for Whom, and for How Long?
- (2013) Christoph U. Correll et al. AMERICAN JOURNAL OF PSYCHIATRY
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. CIRCULATION
- Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database
- (2013) Chris J Bushe et al. JOURNAL OF PSYCHOPHARMACOLOGY
- A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
- (2013) Gail L. Daumit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia
- (2013) Benjamín Cortés et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Unhealthy lifestyle in early psychoses: The role of life stress and the hypothalamic–pituitary–adrenal axis
- (2013) Núria Manzanares et al. PSYCHONEUROENDOCRINOLOGY
- Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight
- (2013) Xueqin Song et al. SCHIZOPHRENIA RESEARCH
- Estado nutricional, ingesta alimentaria y riesgo de enfermedad cardiovascular en individuos con esquizofrenia en el sur de Brasil: estudio de casos-controles
- (2013) Daniela Nunes et al. Revista de Psiquiatria y Salud Mental
- Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight Gain
- (2012) Anil K. Malhotra ARCHIVES OF GENERAL PSYCHIATRY
- Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
- (2012) Marc De Hert et al. CNS DRUGS
- Safety and tolerability of antipsychotic polypharmacy
- (2012) Juan A Gallego et al. Expert Opinion On Drug Safety
- Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine
- (2012) Ludmila A. Kryzhanovskaya et al. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
- Pharmacogenomic Associations With Weight Gain in Olanzapine Treatment of Patients Without Schizophrenia
- (2012) John P. Houston et al. JOURNAL OF CLINICAL PSYCHIATRY
- Weight Change From 3-Year Observational Data
- (2012) Chris J. Bushe et al. JOURNAL OF CLINICAL PSYCHIATRY
- Trajectories of Agouti-Related Protein and Leptin Levels During Antipsychotic-Associated Weight Gain in Patients With Schizophrenia
- (2012) Stefan Ehrlich et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients
- (2012) Arun K. Tiwari et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain
- (2012) Renan P. Souza et al. JOURNAL OF PSYCHIATRIC RESEARCH
- The dietary pattern of patients with schizophrenia: A systematic review
- (2012) Salvatore Dipasquale et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study
- (2012) Yuejin Chen et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain
- (2012) Katrina Weston-Green et al. PLoS One
- Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine–betahistine combination
- (2012) Michael Poyurovsky et al. PSYCHOPHARMACOLOGY
- Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials
- (2012) Jacqueline Caemmerer et al. SCHIZOPHRENIA RESEARCH
- A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
- (2011) T. Scott Stroup et al. AMERICAN JOURNAL OF PSYCHIATRY
- Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
- (2011) Debra L. Foley et al. ARCHIVES OF GENERAL PSYCHIATRY
- Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder
- (2011) Leslie Citrome et al. CLINICAL DRUG INVESTIGATION
- Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics
- (2011) Cristina Cuerda et al. CLINICAL NUTRITION
- Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study
- (2011) Martien Wampers et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
- (2011) M. De Hert et al. EUROPEAN PSYCHIATRY
- Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
- (2011) Lawrence Maayan et al. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- TNF-α −308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment
- (2011) Hsiang-Hsuan Huang et al. NEUROSCIENCE LETTERS
- Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
- (2011) Alex J. Mitchell et al. SCHIZOPHRENIA BULLETIN
- The association between weight change and symptom reduction in the CATIE schizophrenia trial
- (2011) Eric Hermes et al. SCHIZOPHRENIA RESEARCH
- Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat
- (2011) G. C. Smith et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials
- (2010) Christoph U Correll et al. BIPOLAR DISORDERS
- Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics
- (2010) Mehrul Hasnain et al. Current Diabetes Reports
- Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons
- (2010) David Fraguas et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
- (2010) C.U. Correll EUROPEAN PSYCHIATRY
- Management of antipsychotic-related weight gain
- (2010) Lawrence Maayan et al. Expert Review of Neurotherapeutics
- Genetic association between TNF-α −308 G>A polymorphism and longitudinal weight change during clozapine treatment
- (2010) Ying-Chieh Wang et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
- (2010) Brian A Millen et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Appropriate Physical Activity Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults
- (2010) JOSEPH E. DONNELLY et al. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis
- (2010) Lawrence Maayan et al. NEUROPSYCHOPHARMACOLOGY
- Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design
- (2010) Roberto Coccurello et al. PHARMACOLOGY & THERAPEUTICS
- Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
- (2010) Christine Rummel-Kluge et al. SCHIZOPHRENIA BULLETIN
- Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs
- (2010) Tim Moons et al. SCHIZOPHRENIA RESEARCH
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Low-fat oxidation may be a factor in obesity among men with schizophrenia
- (2009) J.-K. Sharpe et al. ACTA PSYCHIATRICA SCANDINAVICA
- Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
- (2009) Mario Álvarez-Jiménez et al. CNS DRUGS
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
- (2009) Christoph U. Correll JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine
- (2009) John W. Newcomer et al. JOURNAL OF CLINICAL PSYCHIATRY
- 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
- (2009) Jari Tiihonen et al. LANCET
- Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey
- (2009) Graham Thornicroft et al. LANCET
- The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?
- (2009) Chao Deng et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?
- (2009) David B. Allison et al. PSYCHIATRY RESEARCH
- Weight gain in antipsychotic-naive patients: a review and meta-analysis
- (2009) I. Tarricone et al. PSYCHOLOGICAL MEDICINE
- Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study
- (2009) Ya Mei Bai et al. SCHIZOPHRENIA RESEARCH
- Weight effects associated with antipsychotics: A comprehensive database analysis
- (2009) Bruce Parsons et al. SCHIZOPHRENIA RESEARCH
- Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder
- (2008) Giuseppe Maina et al. JOURNAL OF AFFECTIVE DISORDERS
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
- (2008) René S Kahn et al. LANCET
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder
- (2008) L HANSSENS et al. SCHIZOPHRENIA RESEARCH
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
- (2008) Jonathan M. Meyer et al. SCHIZOPHRENIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More